CTNNB1 and hepatocellular carcinoma: Specimens from HCC patients (n = 42) and from hepatitis patients (n = 15) were randomly selected from the Protein Array Group, and their CTNNB levels were measured using commercially available ELISA kits from Assay Designs, Inc. Although correlation of immunoassay results with that of antibody array results was poor (R2 = 0.375), the expression level of CTNNB in HCC (median = 651 pg/ml) was significantly higher than that in the hepatitis group (median = 575 pg/ml) (p = 0.025) (Fig. 4A).